State MI
Clinical Trials in Michigan
Michigan is home to a significant concentration of clinical research activity, with academic medical centers, community hospitals, and specialized research clinics serving as active trial sites across a broad range of medical conditions. The studies listed here have at least one enrolled site in Michigan and represent Phase 1 through Phase 4 research sponsored by NIH, pharmaceutical companies, device manufacturers, and independent investigators.
Right now ClinicalMetric tracks 322 actively recruiting studies with Michigan sites out of 322 registered in total. The busiest research areas in Michigan are Advanced Solid Tumors, Small Cell Lung Cancer, Parkinson Disease. Leading sponsors running trials in the state include University of Michigan, National Cancer Institute (NCI), AstraZeneca. By stage, Michigan trials break down as Phase 1 (65), Phase 2 (105), Phase 3 (96), Phase 4 (10).
All trial data is sourced directly from ClinicalTrials.gov and updated daily. Recruiting status, eligibility criteria, enrollment targets, and contact information are included for each study. Patients and caregivers should review the full eligibility criteria on each trial listing — or consult their treating physician — before contacting a study site.
Top Conditions in Michigan
Frequently Asked Questions — Clinical Trials in Michigan
How many clinical trials are currently recruiting in Michigan?
ClinicalMetric currently tracks 322 actively recruiting clinical trials with at least one location in Michigan. The total number of registered studies—including active but not currently enrolling trials—is 322. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Michigan?
Michigan hosts clinical trials across a broad range of medical conditions, including Advanced Solid Tumors, Small Cell Lung Cancer, Parkinson Disease, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Michigan serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Michigan?
To join a clinical trial in Michigan, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Michigan maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Michigan
NCT06317649 Phase 2
Recruiting
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute M...
Condition
Acute Myeloid Leukemia
Enrollment
147 pts
Location
United States, Canada, Puerto Rico
Sponsor
National Cancer Institute (NCI
NCT05573126 Phase 1, Phase 2
Recruiting
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients...
Condition
Hormone Receptor-positive Breast Cancer
Enrollment
95 pts
Location
United States, Spain, United Kingdom
Sponsor
Ellipses Pharma
NCT05139017 Phase 2, Phase 3
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care i...
Condition
DLBCL
Enrollment
290 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT07761117 Phase 3
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Ad...
Condition
Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment
6,950 pts
Location
United States, Argentina, Australia
Sponsor
AstraZeneca
NCT05886920 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subj...
Condition
Advanced Solid Tumors With MAPK Pathway Mutations
Enrollment
67 pts
Location
United States, Australia, China
Sponsor
D3 Bio (Wuxi) Co., Ltd
NCT06615050 Phase 3
Recruiting
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosp...
Condition
Graft-versus-host Disease (GVHD)
Enrollment
572 pts
Location
United States
Sponsor
Incyte Corporation
NCT05172960 N/A
Recruiting
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
Condition
Aortic Stenosis, Severe
Enrollment
1,234 pts
Location
United States, Australia, Canada
Sponsor
Edwards Lifesciences
NCT06094478 N/A
Recruiting
Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Dispos...
Condition
Stroke, Acute
Enrollment
900 pts
Location
United States
Sponsor
University of Chicago
NCT03191149 Phase 2
Recruiting
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Condition
Advanced Lung Non-Small Cell Carcinoma
Enrollment
46 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT03959085 Phase 3
Recruiting
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With ...
Condition
B Acute Lymphoblastic Leukemia
Enrollment
5,951 pts
Location
United States, Australia, Canada
Sponsor
Children's Oncology Group
NCT07795814 Phase 2
Recruiting
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fracti...
Condition
Heart Failure With Preserved Ejection Fraction
Enrollment
90 pts
Location
United States
Sponsor
Edgewise Therapeutics, Inc.
NCT06269510 N/A
Recruiting
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patient...
Condition
Alcohol-related Liver Disease
Enrollment
268 pts
Location
United States
Sponsor
Henry Ford Health System
NCT06745388 Phase 4
Recruiting
Magnesium and Cramping
Condition
Uterine Cramps
Enrollment
150 pts
Location
United States
Sponsor
Corewell Health East
NCT05265273 Phase 2, Phase 3
Recruiting
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized...
Condition
Myasthenia Gravis
Enrollment
12 pts
Location
United States, Japan, Netherlands
Sponsor
Janssen Research & Development
NCT06841354 Phase 3
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Comb...
Condition
Triple Negative Breast Neoplasms
Enrollment
1,000 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT05329129 N/A
Recruiting
OssDsign® Spine Registry Study ("Propel")
Condition
Degenerative Disc Disease
Enrollment
450 pts
Location
United States
Sponsor
OssDsign
NCT06263153 Phase 2
Recruiting
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment...
Condition
Bladder Urothelial Carcinoma
Enrollment
24 pts
Location
United States
Sponsor
Yuanquan Yang
NCT07684235 Phase 3
Recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of ...
Condition
Obesity
Enrollment
3,200 pts
Location
United States, Australia, Canada
Sponsor
Amgen
NCT06376994 Phase 3
Recruiting
Multi-Center Clean Air Randomized Controlled Trial in COPD
Condition
Chronic Obstructive Pulmonary Disease (COPD)
Enrollment
770 pts
Location
United States
Sponsor
JHSPH Center for Clinical Tria
NCT06580561 N/A
Recruiting
Move and Snooze: Adding Insomnia Treatment to an Exercise Program to Improve Pai...
Condition
Knee Osteoarthritis
Enrollment
288 pts
Location
United States
Sponsor
University of Michigan
NCT06730737 N/A
Recruiting
Lifewise Preventive Video Education in Primary Care
Condition
Prevention Harmful Effects
Enrollment
350 pts
Location
United States
Sponsor
Trinity Health-Livonia
NCT06662786 Phase 3
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or ...
Condition
Colorectal Neoplasms
Enrollment
1,000 pts
Location
United States, Belgium, Brazil
Sponsor
Janssen Research & Development
NCT07132645 EARLY_Phase 1
Recruiting
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients W...
Condition
Neuroendocrine Tumor
Enrollment
30 pts
Location
United States
Sponsor
University of Michigan Rogel C
NCT06535854 N/A
Recruiting
Prevail Global Study
Condition
Coronary Artery Disease
Enrollment
1,205 pts
Location
United States, Canada, Germany
Sponsor
Medtronic Vascular
NCT04643002 Phase 1, Phase 2
Recruiting
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Condition
Plasma Cell Myeloma Refractory
Enrollment
258 pts
Location
United States, Australia, France
Sponsor
Sanofi
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology